Patents by Inventor Andrew Lennard
Andrew Lennard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140162969Abstract: There is provided a new use of microspheres comprising a water-insoluble, water-swellable polymer which is anionically charged at pH7, and electrostatically associated with the polymer, in releasable form, a cationically charged chemotherapeutic agent, in the manufacture of a composition for use in the treatment of a brain tumour, wherein in the treatment the composition is introduced into the brain and the chemotherapeutic agent is released from the microspheres, wherein the microspheres, when equilibrated in water at 37° C., comprise at least 40 wt % water based on weight of polymer plus water. Compositions comprising the microspheres and methods for the treatment of brain tumours are also provided.Type: ApplicationFiled: February 14, 2014Publication date: June 12, 2014Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Yiqing TANG, Peter William STRATFORD
-
Patent number: 8691791Abstract: There is provided a new use of microspheres comprising a water-insoluble, water-swellable polymer which is anionically charged at pH7, and electrostatically associated with the polymer, in releasable form, a cationically charged chemotherapeutic agent, in the manufacture of a composition for use in the treatment of a brain tumor, wherein in the treatment the composition is introduced into the brain and the chemotherapeutic agent is released from the microspheres, wherein the microspheres, when equilibrated in water at 37° C., comprise at least 40 wt % water based on weight of polymer plus water. Compositions comprising the microspheres and methods for the treatment of brain tumors are also provided.Type: GrantFiled: October 10, 2007Date of Patent: April 8, 2014Assignee: Biocompatibles UK LimitedInventors: Andrew Lennard Lewis, Yiqing Tang, Peter William Stratford
-
Publication number: 20140030210Abstract: The present disclosure relates to a new polymerisation process in which ethylenically unsaturated monomers are polymerised by a living radical polymerisation process in the presence of an initiator and a catalyst. Polymers produced by this new process are also thought to be novel and may be used to derivatise biological molecules to improve their efficacy as therapeutic treatments. A preferred polymer is of formula The polymers are particularly suitable for derivatising proteins, such as interferon-?.Type: ApplicationFiled: September 26, 2013Publication date: January 30, 2014Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Stephen James BROCCHINI, Antony Robert GODWIN, Yiqing TANG, Andrew Lennard LEWIS
-
Publication number: 20140030350Abstract: The present invention relates to microparticles comprising a gel body, wherein the gel body comprises a synthetic polymer and a drug, wherein the microparticles have an average diameter in the range 40 to 1500 ?m, wherein the polymer is cross-linked by groups comprising disulfide linkages and is in the form of a hydrogel.Type: ApplicationFiled: January 27, 2012Publication date: January 30, 2014Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Koorosh Ashrafi, Andrew Lennard Lewis, Clare Heaysman, Andrew Lloyd, Gary Philips
-
Patent number: 8586098Abstract: A process is described for loading hydrophilic polymer particles with a water-insoluble solvent-soluble drug. The particles are preferably embolic agents. The method provides particles having little or no drug at the surface and in a surface layer, whereby the burst effect is minimised. The drug is precipitated in the core of the particle, leading to extended release. The drug is, for instance, paclitaxel, rapamycin, dexamethasone or ibuprofen.Type: GrantFiled: June 15, 2011Date of Patent: November 19, 2013Assignee: Biocompatibles UK LimitedInventors: Andrew Lennard Lewis, Yiqing Tang, Maria Victoria Gonzalez Fajardo
-
Patent number: 8575397Abstract: The present disclosure relates to a new polymerization process in which ethylenically unsaturated monomers are polymerised by a living radical polymerization process in the presence of an initiator and a catalyst. Polymers produced by this new process are also thought to be novel and may be used to derivatise biological molecules to improve their efficacy as therapeutic treatments. A preferred polymer is of formula The polymers are particularly suitable for derivatising proteins, such as interferon-?.Type: GrantFiled: February 12, 2008Date of Patent: November 5, 2013Assignee: Biocompatibles UK LimitedInventors: Stephen James Brocchini, Antony Robert Godwin, Yiqing Tang, Andrew Lennard Lewis
-
Publication number: 20130243695Abstract: A composition for chemoembolotherapy of solid tumours comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.Type: ApplicationFiled: April 30, 2013Publication date: September 19, 2013Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Peter William STRATFORD, Simon LEPPARD, Pedro GARCIA, Brenda HALL, Maria Victoria Fajardo GONZALEZ
-
Patent number: 8455003Abstract: A composition for chemoembolotherapy of solid tumors comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.Type: GrantFiled: April 20, 2012Date of Patent: June 4, 2013Assignee: Biocompatibles UK LimitedInventors: Andrew Lennard Lewis, Peter William Stratford, Simon Leppard, Pedro Garcia, Brenda Hall, Maria Victoria Fajardo Gonzalez
-
Patent number: 8445612Abstract: An initiator for the terminal group of the polymer product of an atom or group radical transfer polymerisation has an activated carboxyl or an amine group which is reacted with an amine or carboxyl (respectively) group containing biologically active compound. The initiator is preferably 4-(3-(2-bromo, 2-methyl-propionate)phenyl)-propionic acid N-hydroxysuccinimide ester or 2-bromo, 2-methyl-propionic acid N-hydroxysuccinimide ester. The monomers preferably comprise a zwitterionic monomer such as 2-methacryloxyethyl-2?-trimethyl ammoniumethyl phosphate inner salt.Type: GrantFiled: September 23, 2011Date of Patent: May 21, 2013Assignee: Biocompatibles UK LimitedInventors: Andrew Lennard Lewis, Simon William Leppard
-
Patent number: 8431113Abstract: The present invention relates to conjugates of biologically active compounds, preferably therapeutically active compounds, with polymeric moieties having low polydispersity, as well as controlled polymerisation processes for producing the conjugates. An initiation for a controlled radical polymerisation process comprises a biologically active, usually therapeutically active, moiety and the monomer includes zwitterionic monomer for instance 2-methacryloyloxyethyl-2?-trimethylammonium ethyl phosphate inner salt. The process allows close control of the molecular weight and polydispersity of the polymeric moiety and the possibility of optimising the delivery characteristics of the active agent.Type: GrantFiled: September 23, 2011Date of Patent: April 30, 2013Assignee: Biocompatibles UK LimitedInventor: Andrew Lennard Lewis
-
Publication number: 20120276151Abstract: An embolic composition comprises microspheres formed of water-insoluble water-swellable anionic polymer having swollen diameter more than 100 ?m and a cationic camptothecin compound, preferably irinotecan. The microspheres are preferably formed of crosslinked polyvinylalcohol, preferably of ethylenically unsaturated polyvinylalcohol macromer, crosslinked with anionic ethylenically unsaturated anionic comonomer. The compositions are used to treat hypervascular tumours for instance colorectal metastases of the liver.Type: ApplicationFiled: October 27, 2011Publication date: November 1, 2012Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard Lewis, Peter William Stratford, Maria Victoria Gonzalez. Fajardo, Yiqing Tang
-
Publication number: 20120269722Abstract: A composition for chemoembolotherapy of solid tumours comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.Type: ApplicationFiled: April 20, 2012Publication date: October 25, 2012Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Peter William STRATFORD, Simon LEPPARD, Pedro GARCIA, Brenda HALL, Maria Victoria Fajardo GONZALEZ
-
Patent number: 8252878Abstract: A novel class of polymers obtainable by copolymerising a monomer mixture comprising (i) hydrophilic monomer of general formula (I) Y—B—X; (ii) styrene or a substituted styrene, a monomer or mixture of monomers which when polymerized form a polymer with a Tg lower than the Tg of a homopolymer of monomer (I) and lower than the Tg of a homopolymer of monomer (ii); and a monomer having a crosslinkable group is described. The invention also relates to a method for producing such polymers, implants coated with the polymers and methods for forming the same.Type: GrantFiled: July 16, 2007Date of Patent: August 28, 2012Assignee: Biocompatibles UK LimitedInventors: Andrew Lennard Lewis, Sean Willis, Stephen Alister Jones, Vincent James O'Byrne, David Michael Grey, Michael John Driver, Samantha Ryan, Richard Paul Redman
-
Publication number: 20120201867Abstract: An embolic composition comprises microspheres formed of water-insoluble water-swellable anionic polymer having swollen diameter more than 100 ?m, and a cationic camptothecin compound, preferably irinotecan. The microspheres are preferably formed of crosslinked polyvinylalcohol, preferably of ethylenically unsaturated polyvinylalcohol macromer, crosslinked with anionic ethylenically unsaturated anionic comonomer. The compositions are used to treat hypervascular tumours for instance colorectal metastases of the liver.Type: ApplicationFiled: April 20, 2012Publication date: August 9, 2012Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Peter William STRATFORD, Maria Victoria GONZALEZ.FAJARDO, Yiqing TANG
-
Patent number: 8221793Abstract: A composition for chemoembolotherapy of solid tumors comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.Type: GrantFiled: September 15, 2008Date of Patent: July 17, 2012Assignee: Biocompatibles UK LimitedInventors: Andrew Lennard Lewis, Peter William Stratford, Simon Leppard, Pedro Garcia, Brenda Hall, Maria Victoria Fajardo Gonzalez
-
Publication number: 20120157550Abstract: An aqueous composition comprises an amphiphilic block copolymer, having a hydrophilic block comprising pendant zwitterionic groups and a hydrophobic block, and a biologically active compound associated with the polymer. The polymer is preferably in the form of micelles, and preferably the biological active is a hydrophobic drug. The hydrophilic block is preferably formed from acrylic monomer including phosphorylcholine groups. The hydrophobic group is suitably formed from monomer which has groups which can be ionised at useful pH's, especially tertiary amine groups. Micelles may be formed by dissolving the block copolymer in aqueous solvent at a pH at which the amine groups are protonated then raising the pH to a value at which the amine groups are substantially deprotonated, whereupon micelles spontaneously form. The preformed micelles are then contacted with active, under conditions such that solubilisation of the active occurs. The active may be for tumour treatment.Type: ApplicationFiled: January 23, 2012Publication date: June 21, 2012Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Steven Peter ARMES, Andrew W. LLOYD, Jonathan P. SALVAGE
-
Patent number: 8182802Abstract: Compositions are described comprising a of a block copolymer having an overall ionic charge and in which one of the blocks has pendant zwitterionic groups and a biologically active compound having a charge opposite that of the polymer. The polymer is preferably a linear diablock copolymer, preferably having a low polydispersity, such as a (tertiary amine group containing monomer) block-(zwitterionic monomer) copolymer. Suitable cationic monomers are dialkyl aminoalkyl(alk)acrylates and -acrylamides and suitable zwitterionic monomers are phosphorylcholine group containing acrylate monomers such as 2-methacyloyloxyetyl-21-trimethyl ammonium ethyl phosphate liner salt. The biologically active compound is generally polyionic and is for instance a nucleic acid, such as DNA, especially plasmid DNA.Type: GrantFiled: March 7, 2003Date of Patent: May 22, 2012Assignee: Biocompatibles UK LimitedInventors: Andrew Lennard Lewis, Steven Peter Armes
-
Publication number: 20120016082Abstract: An initiator for the terminal group of the polymer product of an atom or group radical transfer polymerisation has an activated carboxyl or an amine group which is reacted with an amine or carboxyl (respectively) group containing biologically active compound. The initiator is preferably 4-(3-(2-bromo, 2-methyl-propionate)phenyl)-propionic acid N-hydroxysuccinimide ester or 2-bromo, 2-methyl-propionic acid N-hydroxysuccinimide ester. The monomers preferably comprise a zwitterionic monomer such as 2-methacryloxyethyl-2?-trimethyl ammoniumethyl phosphate inner salt.Type: ApplicationFiled: September 23, 2011Publication date: January 19, 2012Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Simon William LEPPARD
-
Publication number: 20120016085Abstract: The present invention relates to conjugates of biologically active compounds, preferably therapeutically active compounds, with polymeric moieties having low polydispersity, as well as controlled polymerisation processes for producing the conjugates. An initiation for a controlled radical polymerisation process comprises a biologically active, usually therapeutically active, moiety and the monomer includes zwitterionic monomer for instance 2-methacryloyloxyethyl-2?-trimethylammonium ethyl phosphate inner salt. The process allows close control of the molecular weight and polydispersity of the polymeric moiety and the possibility of optimising the delivery characteristics of the active agent.Type: ApplicationFiled: September 23, 2011Publication date: January 19, 2012Applicant: BIOCOMPATIBLES UK LIMITEDInventor: Andrew Lennard LEWIS
-
Publication number: 20110293731Abstract: A process is described for loading hydrophilic polymer particles with a water-insoluble solvent-soluble drug. The particles are preferably embolic agents. The method provides particles having little or no drug at the surface and in a surface layer, whereby the burst effect is minimised. The drug is precipitated in the core of the particle, leading to extended release. The drug is, for instance, paclitaxel, rapamycin, dexamethasone or ibuprofen.Type: ApplicationFiled: June 15, 2011Publication date: December 1, 2011Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Yiqing TANG, Maria Victoria GONZALEZ FAJARDO